The antifibrinolytic tranexamic acid (TXA) reduced serious bleeding without a significant effect on major vascular outcomes in patients undergoing noncardiac surgery at risk for these complications in ...

For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO)—a common ...

Please provide your email address to receive an email when new articles are posted on . Results showed tranexamic acid administration was not associated with increased mortality, deep venous ...

For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO) – a common ...

Safety of tranexamic acid (TXA), even at higher doses, was upheld in a meta-analysis. Across 216 randomized trials in various medical disciplines, the incidence of thromboembolic events -- including ...

Topical and intravenous tranexamic acid (TXA) were found to significantly reduce blood loss compared with placebo in patients who have undergone bone surgery, suggesting that both administration ...

Prophylactic tranexamic acid (TXA) during cesarean delivery did not lead to a lower risk of maternal death or blood transfusion, a randomized trial found. Among 11,000 women in 31 U.S. hospitals ...

Please provide your email address to receive an email when new articles are posted on . Tranexamic acid was associated with reduced perioperative bleeding in all types of shoulder surgeries and may ...

Within 4 weeks of starting treatment, patients experienced improvements in their condition, indicating an anti-inflammatory effect of the treatment. Study findings are supporting the use of 10% ...

Background The CRASH-2 trial showed that early administration of tranexamic acid (TXA) safely reduces mortality in bleeding in trauma patients. Based on data from the CRASH-2 trial, global mortality ...